Literature DB >> 8384822

Teicoplanin and daptomycin bactericidal activities in the presence of albumin or serum under controlled conditions of pH and ionized calcium.

K C Lamp1, M J Rybak.   

Abstract

Teicoplanin and daptomycin bactericidal rates (BRs) were measured from standard kill curves in supplemented Mueller-Hinton broth (B), B with 3 g of albumin per dl (BA), B with 50% pooled human serum (BS), and in broth to simulate free concentrations (BF) under controlled physiologic conditions of pH (7.4) and ionized calcium (1.15 to 1.17 mM) against two clinical Staphylococcus aureus strains. Total concentrations of teicoplanin and daptomycin, respectively, were 45 and 12.5 micrograms/ml in B, BA, and BS and 4.5 and 1.25 micrograms/ml in BF. All BRs are reported as log10 CFU per milliliter per hour. There was a trend for the teicoplanin BR to be inhibited by serum for strain 67 (BR in B was -0.26 +/- 0.08 versus a BR in BS of -0.19 +/- 0.08 [P > 0.05]). The teicoplanin BRs for strain 135 were unaffected by the type of medium used (range, -0.17 to -0.20). For both strains, daptomycin BRs were adversely affected by lower concentrations, albumin, and serum. The BR of daptomycin was significantly faster in B (-4.53 +/- 1.92) (P < 0.05) than it was in BF (-0.58 +/- 0.04), BA (-1.68 +/- 0.28), or BS (-1.02 +/- 0.16) against strain 67. BA and BS resulted in BRs more than twice that in BF (P > 0.05). Against strain 135, daptomycin again produced the highest BR in B; however, the BRs in BF, BA, and BS were almost identical, indicating that only free daptomycin was active. After correcting for the influence of protein binding, pH, and ionized calcium, teicoplanin appeared to be inhibited by serum, and daptomycin demonstrated enhanced BRs against different S. aureus strains in the presence of albumin or serum.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8384822      PMCID: PMC187715          DOI: 10.1128/AAC.37.3.605

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis.

Authors:  H F Chambers; S Kennedy
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

2.  Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

Review 3.  Therapeutic update on glycopeptide and lipopeptide antibiotics.

Authors:  J C Rotschafer; M W Garrison; K A Rodvold
Journal:  Pharmacotherapy       Date:  1988       Impact factor: 4.705

4.  LY146032: activity and resistance development in vitro.

Authors:  R P Mouton; S L Mulders
Journal:  J Antimicrob Chemother       Date:  1987-10       Impact factor: 5.790

5.  Serum dilution test for bactericidal activity. II. Standardization and correlation with antimicrobial assays and susceptibility tests.

Authors:  L B Reller; C W Stratton
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

6.  Effect of human serum on the bactericidal activity of daptomycin and vancomycin against staphylococcal and enterococcal isolates as determined by time-kill kinetic studies.

Authors:  C W Stratton; L S Weeks
Journal:  Diagn Microbiol Infect Dis       Date:  1990 May-Jun       Impact factor: 2.803

7.  Comparison of in vitro activity of daptomycin, vancomycin and fluoroquinolones in broth and serum against Staphylococcus epidermidis as determined by time-kill kinetics.

Authors:  J R Lentino; R Strodthman
Journal:  Chemotherapy       Date:  1989       Impact factor: 2.544

8.  Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendations.

Authors:  D E Low; A McGeer; R Poon
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

9.  In vitro activities of daptomycin and other antimicrobial agents against vancomycin-resistant gram-positive bacteria.

Authors:  L de la Maza; K L Ruoff; M J Ferraro
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

10.  Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia.

Authors:  M J Rybak; E M Bailey; K C Lamp; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

View more
  10 in total

1.  Defining daptomycin resistance prevention exposures in vancomycin-resistant Enterococcus faecium and E. faecalis.

Authors:  B J Werth; M E Steed; C E Ireland; T T Tran; P Nonejuie; B E Murray; W E Rose; G Sakoulas; J Pogliano; C A Arias; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

Review 2.  Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents.

Authors:  Daniel Gonzalez; Stephan Schmidt; Hartmut Derendorf
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

3.  Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.

Authors:  Ashley D Hall; Molly E Steed; Cesar A Arias; Barbara E Murray; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

4.  Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium.

Authors:  R C Mercier; H H Houlihan; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

5.  In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.

Authors:  M J Rybak; E Hershberger; T Moldovan; R G Grucz
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

6.  Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens.

Authors:  D R Snydman; N V Jacobus; L A McDermott; J R Lonks; J M Boyce
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

7.  Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model.

Authors:  Elizabeth D Hermsen; Laurie B Hovde; John R Hotchkiss; John C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

8.  Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis.

Authors:  B J McGrath; S L Kang; G W Kaatz; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

Review 9.  Daptomycin.

Authors:  Caroline Fenton; Gillian M Keating; Monique P Curran
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 10.  Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D H Peters
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.